SPRY ARS Pharmaceuticals Inc

Price (delayed)

$9.075

Market cap

$901.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.01

Enterprise value

$1.05B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 14

Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically ...

Highlights
SPRY's revenue is up by 17% since the previous quarter
SPRY's gross profit is down by 23% year-on-year but it is up by 15% since the previous quarter
ARS Pharmaceuticals's debt has soared by 146% YoY
ARS Pharmaceuticals's equity has plunged by 73% YoY and by 46% from the previous quarter

Key stats

What are the main financial stats of SPRY

SPRY stock price

How has the ARS Pharmaceuticals stock price performed over time
Intraday
3.71%
1 week
-3.46%
1 month
2.77%
1 year
-34.33%
YTD
-22.1%
QTD
13.01%

Financial performance

How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$98.99M
Gross profit
$73.37M
Operating income
-$202.42M
Net income
-$197.98M
Gross margin
74.1%
Net margin
-200%
ARS Pharmaceuticals's gross margin has decreased by 24% YoY and by 2.2% from the previous quarter
SPRY's gross profit is down by 23% year-on-year but it is up by 15% since the previous quarter
SPRY's revenue is up by 17% since the previous quarter
The net income has decreased by 16% QoQ

Price vs fundamentals

How does SPRY's price correlate with its fundamentals

Growth

What is ARS Pharmaceuticals's growth rate over time

Valuation

What is ARS Pharmaceuticals stock price valuation
P/E
N/A
P/B
14.7
P/S
9.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.59
SPRY's EPS is down by 16% since the previous quarter
ARS Pharmaceuticals's equity has plunged by 73% YoY and by 46% from the previous quarter
The price to book (P/B) is 46% higher than the last 4 quarters average of 9.7
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 7471.0 and 20% lower than the last 4 quarters average of 11.0
SPRY's revenue is up by 17% since the previous quarter

Efficiency

How efficient is ARS Pharmaceuticals business performance
SPRY's ROE has plunged by 53% from the previous quarter
The company's return on assets fell by 19% QoQ
SPRY's return on invested capital is down by 11% since the previous quarter
SPRY's return on sales is up by 2.6% since the previous quarter

Dividends

What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRY.

Financial health

How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's total assets is 27% more than its total liabilities
ARS Pharmaceuticals's total liabilities has surged by 130% YoY and by 6% QoQ
The company's current ratio has shrunk by 55% YoY and by 32% QoQ
ARS Pharmaceuticals's debt is 179% more than its equity
ARS Pharmaceuticals's debt has soared by 146% YoY
The company's debt to equity has surged by 90% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.